DK2117587T3 - Bakterieekstrakt til lidelser i fordøjelseskanalen eller urinvejene og fremgangsmåde til fremstilling deraf - Google Patents
Bakterieekstrakt til lidelser i fordøjelseskanalen eller urinvejene og fremgangsmåde til fremstilling deraf Download PDFInfo
- Publication number
- DK2117587T3 DK2117587T3 DK08731429.0T DK08731429T DK2117587T3 DK 2117587 T3 DK2117587 T3 DK 2117587T3 DK 08731429 T DK08731429 T DK 08731429T DK 2117587 T3 DK2117587 T3 DK 2117587T3
- Authority
- DK
- Denmark
- Prior art keywords
- extract
- bacterial
- lysis
- amino acids
- concentration
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0258—Escherichia
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P1/00—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes
- C12P1/04—Preparation of compounds or compositions, not provided for in groups C12P3/00 - C12P39/00, by using microorganisms or enzymes by using bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/08—Clostridium, e.g. Clostridium tetani
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P13/00—Preparation of nitrogen-containing organic compounds
- C12P13/04—Alpha- or beta- amino acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P19/00—Preparation of compounds containing saccharide radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S435/00—Chemistry: molecular biology and microbiology
- Y10S435/8215—Microorganisms
- Y10S435/822—Microorganisms using bacteria or actinomycetales
- Y10S435/848—Escherichia
- Y10S435/849—Escherichia coli
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Reproductive Health (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Gynecology & Obstetrics (AREA)
- Pain & Pain Management (AREA)
- Pregnancy & Childbirth (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Claims (23)
- BAKTERIEEKSTRAKT TIL LIDELSER I FORDØJELSESKANALEN ELLER URINVEJENE OG FREMGANGSMÅDE TIL FREMSTILLING DERAF Patentkrav1. Ekstrakt, der omfatter bakterielysat fra alle de Escherichia co//-bakteriestammer, som er valgt blandt NCTC: 8603, 8621, 8622, 8623, 9026, 9111,9119, 9707, 9708,1: 081, 082, 083, 084, 085, 086, 087, 088 og 089, og som bevarer og/eller tilbageholder lipopolysaccharidbestanddele, der kan opnås ved at lysere bakteriestammerne ved en initial pH-værdi på mere end 12, hvor ekstraktet omfatter mindst 0,3 mg/ml saccharider, mindre end 100pg/ml nukleinsyrer, mellem 1,5 og 2,5 mg/ml frie aminosyrer i ækvivalenter af glutaminsyre (147,1 g/mol), som er valgt blandt asparaginsyre, glutaminsyre, serin, histidin, alanin, arginin, tyrosin, methionin, phenylalanin og lysin, der er racemiseret med mindst 10 %, og hvor ekstraktet ikke udgør en risiko for prionsygdomme.
- 2. Ekstrakt ifølge krav 1, hvor ekstraktet omfatter mellem 0,3 og 4,5 mg/ml saccharider.
- 3. Ekstrakt ifølge krav 1, hvor mindst ét saccharid, der kan være forgrenet polysaccharid, er valgt fra gruppen bestående af monosaccharider, disaccharider og polysaccharider.
- 4. Ekstrakt ifølge krav 3, hvor mindst ét saccharid er kemisk modificeret.
- 5. Ekstrakt ifølge krav 4, hvor hver bakteriestamme, hvorfra ekstraktet er afledt, dyrkes i et vegetabilsk eller syntetisk medium.
- 6. Ekstrakt ifølge et hvilket som helst af kravene 1 til 5, hvor de frie aminosyrer i ekstraktet omfatter mellem 1 og 80 % D-aminosyrer, fortrinsvis mellem 10 og 45 % D-aminosyrer, mere fortrinsvis mellem 25 og 35 % D-aminosyrer.
- 7. Ekstrakt ifølge et hvilket som helst af kravene 1-6, hvor ekstraktet omfatter mindst én D-aminosyre, som er valgt blandt D-asparaginsyre og D-asparagin, D-glutaminsyre og D-glutamin, D-serin, D-methionin, D-histidin, D-alanin, D-arginin, D-phenylalanin, D-tyrosin, D-leucin, D-lysin, D-valin og D-threonin.
- 8. Ekstrakt ifølge krav 7, hvor koncentrationen af en hvilken som helst D-aminosyre er mellem 1 og 50 % af koncentrationen af frie aminosyrer, fortrinsvis mellem 10 og 40 % af koncentrationen af frie aminosyrer, mere fortrinsvis mellem 15 og 35 % af koncentrationen af frie aminosyrer.
- 9. Ekstrakt ifølge et hvilket som helst af kravene 1-8, hvor ekstraktet omfatter mindre end 5000 ng LPS-ækvivalenter ved en kromogen Limulus-amoebocyt-lysat-(LAL)-test.
- 10. Ekstrakt ifølge krav 9, hvor det ene eller flere proteiner har en molekylvægt på mindre end 30 kDa.
- 11. Farmaceutisk sammensætning, der omfatter ekstraktet ifølge et hvilket som helst af kravene 1-10.
- 12. Anvendelse af ekstrakt ifølge et hvilket som helst af kravene 1 til 10 til fremstilling af et medikament til behandling og/eller forebyggelse af lidelser i fordøjelseskanalen eller urinvejene hos et menneskeindivid eller et huspattedyr.
- 13. Ekstrakt ifølge et hvilket som helst af kravene 1-10 til anvendelse i en fremgangsmåde til behandling og/eller forebyggelse af lidelser i fordøjelseskanalen eller urinvejene hos et menneskeindivid eller et huspattedyr.
- 14. Anvendelse ifølge krav 13, hvor lidelsen i fordøjelseskanalen eller urinvejene er valgt blandt urethritis, tubulointerstitiel nephritis, obstruktiv pyelonephritis, urinvejsinfektioner som følge af uropati ved obstruktion og refluks, cystitis, herunder kronisk cystitis, prostatitis, herunder kronisk prostatitis, prostatocystitis, inflammatoriske bækkensygdomme hos kvinder, Crohns sygdom og irritabel tarm-syndrom.
- 15. Ekstrakt til anvendelse i en fremgangsmåde ifølge krav 13, hvor lidelsen i fordøjelseskanalen eller urinvejene er valgt blandt urethritis, tubulointerstitiel nephritis, obstruktiv pyelonephritis, urinvejsinfektioner som følge af uropati ved obstruktion og refluks, cystitis, herunder kronisk cystitis, prostatitis, herunder kronisk prostatitis, prostatocystitis, inflammatoriske bækkensygdomme hos kvinder, Crohns sygdom og irritabel tarm-syndrom.
- 16. Fremgangsmåde til fremstilling af et ekstrakt ifølge et hvilket som helst af kravene 1 til 10 ud fra en blanding af alle de stammer af E. coli, som er valgt blandt: NCTC: 8603, 8621, 8622, 8623, 9026, 9111,9119, 9707 og 9708 samt I: 081,082, 083, 084, 085, 086, 087, 088 og 089, hvilken fremgangsmåde omfatter: (a) dyrkning af hver stamme i et medium, der ikke udgør en risiko for prionsygdomme; (b) lysering af hver stamme ved en initial phl-værdi på mere end 12; og (c) passage af produktet i (b) mindst én gang gennem et mikrofilter og mindst én gang gennem et ultrafilter.
- 17. Fremgangsmåde ifølge krav 16, hvor lysen udføres ved en initial phl-værdi på mere end 12,5, fortrinsvis ved en initial phl-værdi på 12,6 til 13,4.
- 18. Fremgangsmåde ifølge et hvilket som helst af kravene 16-17, hvor mindst en del af lysen udføres ved en initial hydroxidionkoncentration på 0,1 N til 1,1 N, fortrinsvis ved en initial hydroxidionkoncentration på 0,2 N til 1 N.
- 19. Fremgangsmåde ifølge et hvilket som helst af kravene 16-18, hvor mindst en del af lysen udføres i et tidsrum på 30 til 50 timer ved 30 til 40 °C, fortrinsvis i et tidsrum på 60 til 120 timer ved 30 til 40 °C.
- 20. Fremgangsmåde ifølge et hvilket som helst af kravene 16-19, hvor mikrofiltret er 0,45 mikrometer, og ultrafiltret er 30 KDa.
- 21. Fremgangsmåde ifølge et hvilket som helst af kravene 16-20, der endvidere omfatter passage af produktet i (c) gennem et andet mikrofilter ved 0,2 mikrometer.
- 22. Fremgangsmåde ifølge et hvilket som helst af kravene 16-21, hvor del (c) foretages ved tangential-flow-filtrering, fortrinsvis foretaget i 5 til 15 cykler.
- 23. Fremgangsmåde ifølge et hvilket som helst af kravene 16-22, hvor del (b) udføres med 10-120 g/l bakteriel materialetørvægt.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90478707P | 2007-03-05 | 2007-03-05 | |
| PCT/US2008/055902 WO2008109667A2 (en) | 2007-03-05 | 2008-03-05 | Bacterial extract for digestive or urinary tract disorders and process for its preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK2117587T3 true DK2117587T3 (da) | 2018-04-30 |
Family
ID=39739085
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK08731429.0T DK2117587T3 (da) | 2007-03-05 | 2008-03-05 | Bakterieekstrakt til lidelser i fordøjelseskanalen eller urinvejene og fremgangsmåde til fremstilling deraf |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US8236522B2 (da) |
| EP (2) | EP2117587B1 (da) |
| JP (2) | JP6041458B2 (da) |
| KR (1) | KR101666548B1 (da) |
| CN (1) | CN101743019B (da) |
| AR (2) | AR068348A1 (da) |
| AU (1) | AU2008222863B2 (da) |
| BR (1) | BRPI0808351A2 (da) |
| CA (1) | CA2679983C (da) |
| DK (1) | DK2117587T3 (da) |
| ES (1) | ES2664990T3 (da) |
| HU (1) | HUE038602T2 (da) |
| IL (1) | IL200665A (da) |
| MX (1) | MX2009009451A (da) |
| PL (1) | PL2117587T3 (da) |
| PT (1) | PT2117587T (da) |
| RU (1) | RU2457848C2 (da) |
| SI (1) | SI2117587T1 (da) |
| TW (1) | TWI549682B (da) |
| WO (1) | WO2008109667A2 (da) |
| ZA (1) | ZA200906028B (da) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2902799B1 (fr) | 2006-06-27 | 2012-10-26 | Millipore Corp | Procede et unite de preparation d'un echantillon pour l'analyse microbiologique d'un liquide |
| PL2114421T3 (pl) * | 2007-03-05 | 2018-07-31 | Om Pharma | Ekstrakt bakteryjny do stosowania względem zaburzeń oddechowych i sposób jego wytwarzania |
| SG171446A1 (en) * | 2008-12-16 | 2011-07-28 | Millipore Corp | Stirred tank reactor and method |
| CN102892791B (zh) | 2010-05-17 | 2017-05-17 | Emd密理博公司 | 用于纯化生物分子的刺激响应性聚合物 |
| EA201891926A1 (ru) | 2017-02-03 | 2019-04-30 | Киверди, Инк. | Микроорганизмы и искусственные экосистемы для производства белка, продуктов питания и полезных побочных продуктов из субстратов c1 |
| US10238906B1 (en) | 2017-06-29 | 2019-03-26 | Dennis Doyle | Gluteus maximus exercise device |
| CN109762763A (zh) * | 2019-01-24 | 2019-05-17 | 天津大学 | 添加d-氨基酸混合物培养基及其制备方法与应用 |
| JP2022525177A (ja) * | 2019-03-14 | 2022-05-11 | オーエム ファーマ | 安定細菌抽出物を作製するプロセス及び医薬としてのその使用 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH639852A5 (fr) | 1979-07-26 | 1983-12-15 | Om Laboratoires Sa | Medicament contre les maladies infectieuses des voies urinaires et digestives. |
| US4853143A (en) | 1987-03-17 | 1989-08-01 | The Procter & Gamble Company | Bleach activator compositions containing an antioxidant |
| US4952500A (en) * | 1988-02-01 | 1990-08-28 | University Of Georgia Research Foundation, Inc. | Cloning systems for Rhodococcus and related bacteria |
| US4912094B1 (en) * | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| FR2649116B1 (fr) | 1989-06-29 | 1991-09-27 | Rhone Poulenc Chimie | Composition organopolysiloxane monocomposante a stabilite au stockage amelioree |
| JPH054929A (ja) * | 1991-02-08 | 1993-01-14 | Nippon Chem Res Kk | 抗ウイルス活性物質の分画精製方法 |
| CH685498A5 (fr) | 1992-02-14 | 1995-07-31 | Om Lab Sa | Extrait de macromolécules bactériennes, procédé pour sa préparation et composition pharmaceutique contenant cet extrait. |
| DE69600242T2 (de) * | 1995-09-07 | 1998-08-06 | Oreal | Verwendung von Extrakten aus filamentösen, nicht photosynthetischen Bakterien sowie ihre Zusammensetzungen |
| FR2753101B1 (fr) * | 1996-09-12 | 1998-11-06 | Algues Et Mer Sarl | Extrait d'algues, composition cosmetique comportant un tel extrait et utilisation de cet extrait en tant qu'agent antibacterien et/ou antifongique |
| US7375188B2 (en) | 2005-07-29 | 2008-05-20 | Mallinckrodt Baker, Inc. | Vegetarian protein a preparation and methods thereof |
| JP5286089B2 (ja) * | 2006-01-13 | 2013-09-11 | バクスター・インターナショナル・インコーポレイテッド | ポリサッカライドを精製する方法 |
-
2008
- 2008-03-05 BR BRPI0808351-7A2A patent/BRPI0808351A2/pt not_active Application Discontinuation
- 2008-03-05 RU RU2009136579/15A patent/RU2457848C2/ru active
- 2008-03-05 DK DK08731429.0T patent/DK2117587T3/da active
- 2008-03-05 JP JP2009552857A patent/JP6041458B2/ja active Active
- 2008-03-05 CA CA2679983A patent/CA2679983C/en active Active
- 2008-03-05 KR KR1020097018711A patent/KR101666548B1/ko active IP Right Grant
- 2008-03-05 ES ES08731429.0T patent/ES2664990T3/es active Active
- 2008-03-05 PL PL08731429T patent/PL2117587T3/pl unknown
- 2008-03-05 EP EP08731429.0A patent/EP2117587B1/en active Active
- 2008-03-05 WO PCT/US2008/055902 patent/WO2008109667A2/en active Application Filing
- 2008-03-05 US US12/530,159 patent/US8236522B2/en active Active
- 2008-03-05 MX MX2009009451A patent/MX2009009451A/es active IP Right Grant
- 2008-03-05 CN CN200880010610.2A patent/CN101743019B/zh active Active
- 2008-03-05 PT PT87314290T patent/PT2117587T/pt unknown
- 2008-03-05 EP EP18150868.0A patent/EP3332806A1/en not_active Withdrawn
- 2008-03-05 SI SI200831935T patent/SI2117587T1/en unknown
- 2008-03-05 AU AU2008222863A patent/AU2008222863B2/en active Active
- 2008-03-05 HU HUE08731429A patent/HUE038602T2/hu unknown
- 2008-08-26 AR ARP080103704 patent/AR068348A1/es active IP Right Grant
- 2008-09-01 TW TW097133418A patent/TWI549682B/zh active
-
2009
- 2009-08-31 ZA ZA2009/06028A patent/ZA200906028B/en unknown
- 2009-09-01 IL IL200665A patent/IL200665A/en active IP Right Grant
-
2012
- 2012-06-20 US US13/528,520 patent/US9017743B2/en active Active
-
2015
- 2015-01-15 US US14/597,254 patent/US9198961B2/en active Active
- 2015-03-02 JP JP2015040257A patent/JP2015129171A/ja active Pending
-
2018
- 2018-05-22 AR ARP180101346A patent/AR111819A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9198961B2 (en) | Bacterial extract for digestive or urinary tract disorders and process for its preparation | |
| DK2114421T3 (da) | Bakterieekstrakt til åndedrætslidelser og fremgangsmåde til fremstilling deraf | |
| AU2013200193B2 (en) | Bacterial extract for digestive or urinary tract disorders and process for its preparation | |
| AU2013202504B2 (en) | Bacterial extract for respiratory disorders and process for its preparation | |
| TW201010711A (en) | Immunomodulatory extracts from lactobacillus bacteria and methods of manufacturing and use thereof |